Another epilepsy/pain/depression drug which can potentially relieve tinnitus.
The article mentioned can be found here:
Can GABAkines Quiet the Noise? The GABAA Receptor Neurobiology and Pharmacology of Tinnitus
RespireRx Pharmaceuticals highlights experimental data suggesting its GABAkine KRM-II-81 could be game-changing for tinnitus patients
RespireRx Pharmaceuticals Inc has announced that members of the company's scientific team have published a new article highlighting the potential of novel treatments, including the company's own GABAkine KRM-II-81 for tinnitus, the perception of sound in the absence of external auditory stimulation.
First author of the article and RespireRx research fellow Jeffrey Witkin said the experimental data on GABA suggested the possibility that GABAkines such as RespireRx's KRM-II-81 could be game-changing for tinnitus patients.
In the article "Can GABAkines Quiet the Noise? The GABAA Receptor Neurobiology and Pharmacology of Tinnitus" published in Biochemical Pharmacology, Witkin along with other RespireRx scientific team members Rok Cerne, James Cook, and Arnold Lippa and neurosurgeon with Ascension St. Vincent in Indianapolis Jodi Smith reviewed evidence that the loss of neural inhibition due to alterations in GABA neurotransmission may play a role in the etiology of tinnitus.
The authors reviewed data sets which strongly supported the concept that the downregulation of GABA, the primary inhibitory neurotransmitter in the brain, and/or its receptors may act as a key regulatory for tinnitus, as supported by individual patient reports and clinical trials that reported improvements in tinnitus symptoms with the use of older generation positive allosteric modulators of GABA (GABAkines).
"We wrote this review and commentary in Biochemical Pharmacology with the hope that it would infuse renewed energy into the search for new medicinal treatments," Witkin said.
"It is a blessing to see experimental compounds ultimately put to use in the alleviation of suffering."
RespireRx Pharmaceuticals Inc has announced that members of the company's scientific team have published a new article highlighting the potential of novel treatments, including the company's own GABAkine KRM-II-81 for tinnitus, the perception of sound in the absence of external auditory stimulation.
First author of the article and RespireRx research fellow Jeffrey Witkin said the experimental data on GABA suggested the possibility that GABAkines such as RespireRx's KRM-II-81 could be game-changing for tinnitus patients.
In the article "Can GABAkines Quiet the Noise? The GABAA Receptor Neurobiology and Pharmacology of Tinnitus" published in Biochemical Pharmacology, Witkin along with other RespireRx scientific team members Rok Cerne, James Cook, and Arnold Lippa and neurosurgeon with Ascension St. Vincent in Indianapolis Jodi Smith reviewed evidence that the loss of neural inhibition due to alterations in GABA neurotransmission may play a role in the etiology of tinnitus.
The authors reviewed data sets which strongly supported the concept that the downregulation of GABA, the primary inhibitory neurotransmitter in the brain, and/or its receptors may act as a key regulatory for tinnitus, as supported by individual patient reports and clinical trials that reported improvements in tinnitus symptoms with the use of older generation positive allosteric modulators of GABA (GABAkines).
"We wrote this review and commentary in Biochemical Pharmacology with the hope that it would infuse renewed energy into the search for new medicinal treatments," Witkin said.
"It is a blessing to see experimental compounds ultimately put to use in the alleviation of suffering."
The article mentioned can be found here:
Can GABAkines Quiet the Noise? The GABAA Receptor Neurobiology and Pharmacology of Tinnitus
Member
